Meike Brinker

Featured in: Favicon

Articles

Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes | Nature Medicine

Oct 28, 2024 | nature.com | Pardeep S. Jhund |Meike Brinker |Peter Kolkhof |Michele Senni |Sanjiv Shah |Adriaan A. Voors | +3 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03264-4, published online 1 September 2024. In the version of the article initially published, the first three columns of the “New-onset atrial fibrillation” row of Fig. 1 originally read “286 (3.0)”, “1.3”, “345 (3.6)” and have now been amended to “286 (3.9)”, “1.4”, “345 (4.7)” in the HTML and PDF versions of the article.
Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes | Nature Medicine

Sep 1, 2024 | nature.com | Pardeep S. Jhund |Meike Brinker |Peter Kolkhof |Michele Senni |Sanjiv Shah |Adriaan A. Voors | +3 more

AbstractCardiovascular-kidney-metabolic syndrome is an emerging entity that connects cardiovascular diseases, chronic kidney disease, and diabetes. The non-steroidal mineralocorticoid receptor antagonist, finerenone, has been studied in three prospective randomized clinical trials of patients with cardio-kidney-metabolic syndrome: FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.